Bubs Australia’s US weekly scan revenue has exceeded US$1 million, up from the Q3 average of US$750,000, setting a new record for the company.
The company reported selling more than 24,000 tins per week and becoming the No 1 best-selling infant formula product on Amazon USA last month, a significant increase from its previous ranking of sixth.
Reg Weine, CEO and MD of Bubs, said the company recently increased its inventory levels in the US to meet rising demand following the stock shortages that occurred late last year.
“We are seeing sustained demand for our products across the US, from more than 5800 bricks and mortar retail stores stocking Bubs,” he added.
Meanwhile, its progress on the FDA permanent access pathway and clinical trial shows continued momentum, with more than 300 infant enrolments, or 75 per cent of the target enrolled this month, compared to 212 in March.
The goat’s milk infant formula producer has also started rolling out new label tins and sizes for the US market.
“Our recent brand performance is a testament to our premium, high quality, clean label nutritional options that continue to resonate with US parents and healthcare professionals,” Weine concluded.
